Sivik Global Healthcare’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q1 | – | Sell |
-13,000
| Closed | -$5.24M | – | 41 |
|
2024
Q4 | $5.24M | Buy |
13,000
+3,000
| +30% | +$1.21M | 2.76% | 15 |
|
2024
Q3 | $4.65M | Sell |
10,000
-5,000
| -33% | -$2.33M | 1.97% | 25 |
|
2024
Q2 | $7.03M | Buy |
15,000
+4,000
| +36% | +$1.87M | 2.53% | 13 |
|
2024
Q1 | $4.6M | Sell |
11,000
-1,500
| -12% | -$627K | 1.08% | 31 |
|
2023
Q4 | $5.09M | Buy |
12,500
+40
| +0.3% | +$16.3K | 2.12% | 29 |
|
2023
Q3 | $4.33M | Sell |
12,460
-1,540
| -11% | -$536K | 2.19% | 27 |
|
2023
Q2 | $4.93M | Sell |
14,000
-1,000
| -7% | -$352K | 1.15% | 28 |
|
2023
Q1 | $4.73M | Hold |
15,000
| – | – | 2.03% | 27 |
|
2022
Q4 | $4.33M | Buy |
+15,000
| New | +$4.33M | 2.04% | 26 |
|
2021
Q2 | – | Sell |
-15,000
| Closed | -$3.22M | – | 61 |
|
2021
Q1 | $3.22M | Buy |
+15,000
| New | +$3.22M | 1.18% | 37 |
|
2020
Q3 | – | Sell |
-30,000
| Closed | -$5.63M | – | 59 |
|
2020
Q2 | $5.63M | Buy |
30,000
+5,000
| +20% | +$938K | 1.87% | 23 |
|
2020
Q1 | $4.43M | Sell |
25,000
-7,500
| -23% | -$1.33M | 1.75% | 26 |
|
2019
Q4 | $7.12M | Sell |
32,500
-7,500
| -19% | -$1.64M | 2.64% | 15 |
|
2019
Q3 | $6.78M | Buy |
40,000
+10,000
| +33% | +$1.69M | 3.42% | 6 |
|
2019
Q2 | $5.5M | Hold |
30,000
| – | – | 1.33% | 18 |
|
2019
Q1 | $5.52M | Sell |
30,000
-5,000
| -14% | -$920K | 2.03% | 22 |
|
2018
Q4 | $5.8M | Hold |
35,000
| – | – | 3.13% | 11 |
|
2018
Q3 | $6.75M | Sell |
35,000
-8,600
| -20% | -$1.66M | 2.41% | 15 |
|
2018
Q2 | $7.41M | Buy |
43,600
+8,600
| +25% | +$1.46M | 2.85% | 6 |
|
2018
Q1 | $5.7M | Sell |
35,000
-10,000
| -22% | -$1.63M | 2.66% | 11 |
|
2017
Q4 | $6.74M | Sell |
45,000
-5,000
| -10% | -$749K | 2.5% | 8 |
|
2017
Q3 | $7.6M | Sell |
50,000
-5,000
| -9% | -$760K | 2.59% | 10 |
|
2017
Q2 | $7.09M | Buy |
55,000
+5,000
| +10% | +$644K | 2.59% | 9 |
|
2017
Q1 | $5.47M | Buy |
50,000
+10,000
| +25% | +$1.09M | 2.55% | 12 |
|
2016
Q4 | $2.95M | Sell |
40,000
-10,000
| -20% | -$737K | 1.41% | 29 |
|
2016
Q3 | $4.36M | Sell |
50,000
-15,000
| -23% | -$1.31M | 2.2% | 24 |
|
2016
Q2 | $5.59M | Buy |
65,000
+45,000
| +225% | +$3.87M | 2.78% | 6 |
|
2016
Q1 | $1.59M | Sell |
20,000
-10,000
| -33% | -$795K | 0.7% | 52 |
|
2015
Q4 | $3.78M | Sell |
30,000
-10,000
| -25% | -$1.26M | 1.79% | 23 |
|
2015
Q3 | $4.17M | Buy |
40,000
+23,000
| +135% | +$2.4M | 2.02% | 21 |
|
2015
Q2 | $2.1M | Buy |
+17,000
| New | +$2.1M | 0.73% | 53 |
|
2015
Q1 | – | Sell |
-14,900
| Closed | -$1.77M | – | 80 |
|
2014
Q4 | $1.77M | Sell |
14,900
-15,100
| -50% | -$1.79M | 0.72% | 58 |
|
2014
Q3 | $3.37M | Buy |
30,000
+10,000
| +50% | +$1.12M | 1.53% | 29 |
|
2014
Q2 | $1.89M | Buy |
+20,000
| New | +$1.89M | 0.96% | 46 |
|